<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200625</url>
  </required_header>
  <id_info>
    <org_study_id>20190944</org_study_id>
    <nct_id>NCT04200625</nct_id>
  </id_info>
  <brief_title>Semaglutide vs Dulaglutide on Epicardial Adipose Tissue</brief_title>
  <official_title>Effects of Semaglutide vs Dulaglutide on Epicardial Adipose Tissue Thickness in Subjects With Type 2 Diabetes and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic
      risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor
      agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of
      GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective, observational, case control study. Data were obtained from
      retrospective review of the electronic medical records.

      Patients were treated with either semaglutide, dulaglutide or metformin as standard of care,
      during routine clinical practice, regardless of the study. Each patient underwent routine
      labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine
      12-week follow up visit, as standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Actual">December 9, 2019</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Epicardial Fat thickness</measure>
    <time_frame>12 weeks</time_frame>
    <description>Ultrasound measured Epicardial Fat thickness</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Epicardial Fat</condition>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <description>Patients using standard of care weekly GLP-1A analog Semaglutide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <description>Patients using standard of care weekly GLP-1A analog Dulaglutide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <description>Patients using standard of care daily Metformin.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetic subjects who routinely come to the University of Miami Division of
        Diabetes, Endocrinology and Metabolism outpatient diabetic clinic, as standard of care.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes,

          -  BMI ≥27 kg/m2,

          -  Age ≥ 18 years old

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors or other GLP-1 agonist
             receptors

          -  History of diabetic ketoacidosis

          -  Known contraindications to GLP-1 receptor agonists such as previous history of
             pancreatitis or medullary thyroid carcinoma, personal or family history of multiple
             endocrine neoplasia type 2

          -  Acute infective diseases, cancer or chemotherapy

          -  Use of systemic corticosteroids within the 3 months prior this study

          -  Known or suspected allergy to semaglutide or dulaglutide excipients or related
             products

          -  Pregnancy, breastfeeding or the intention of becoming pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianluca Iacobellis, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Gianluca Iacobellis</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

